Document:

QUANTUM
MATERIALS CORP.

WARRANTS

 

THE
WARRANTS EVIDENCED HEREBY AND THE SECURITIES ISSUABLE UPON THE EXERCISE THEREOF ARE SUBJECT TO THE TERMS AND CONDITIONS OF THAT
CERTAIN UNIT SUBSCRIPTION AGREEMENT AMONG QUANTUM MATERIALS CORP., A NEVADA CORPORATION (THE “COMPANY”), AND
THE PERSON IDENTIFIED AT THE END OF THIS INSTRUMENT AS THE INVESTOR (THE “INVESTOR”), DATED AS OF THE DATE
HEREOF, AS THE SAME MAY BE AMENDED FROM TIME TO TIME (THE “UNIT SUBSCRIPTION AGREEMENT”).

 

NEITHER
THE WARRANTS GRANTED HEREIN NOR THE UNDERLYING SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY STATE OR OTHER SECURITIES LAW. THE HOLDER HEREOF, BY ACQUIRING THIS INSTRUMENT, AGREES
THAT THESE WARRANTS MAY BE RESOLD, PLEDGED, EXERCISED OR OTHERWISE TRANSFERRED SOLELY IN ACCORDANCE WITH THE TERMS HEREOF, THE
UNIT SUBSCRIPTION AGREEMENT AND (A) ONLY (1) PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR
(2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES
LAWS OF ANY STATE OF THE UNITED STATES AND (B) PURSUANT TO AN AVAILABLE EXEMPTION OR EFFECTIVE REGISTRATION UNDER ANY OTHER APPLICABLE
SECURITIES LAWS.

 

This
Warrant is granted pursuant to the terms and conditions of the Unit Subscription Agreement. Unless otherwise defined herein, capitalized
terms have the definitions ascribed thereto in the Unit Subscription Agreement.

 

This
certifies that the Investor is the holder of warrants to purchase (the “Warrants”) [________] shares of Common
Stock, par value $0.001 per share, of the Company (“Common Stock”) at a purchase price equal to the Exercise
Price (such shares of Common Stock, the “Applicable Shares”). The exercise price, which shall be deliverable
upon the exercise of each Warrant, shall be $0.15 per share of Common Stock as such price may be amended from time to time as
provided herein (the “Exercise Price”). The Applicable Shares shall be deliverable upon surrender of this instrument
and payment of such Exercise Price to the Company, but subject to the conditions set forth herein. Payment of the Exercise Price
shall be made in immediately available funds and shall be accompanied by the Form of Exercise attached hereto properly completed
by the holder.

 

The
Warrants evidenced hereby shall be exercisable at any time and from time to time for Applicable Securities upon the exercise thereof
in accordance with the terms hereof; provided however, that the Warrants may not be exercised after (and shall expire
upon the occurrence of) the earlier to occur of (i) the fifth (5th) anniversary of the date hereof, and (ii) the closing of a
Significant Corporate Event. A “Significant Corporate Event” means any of the following events: (A) an underwritten
public offering of Company securities, (B) the Company merges or consolidates with or into another entity in a transaction in
which the equity security holders of the Company do not own 50% or more of the equity securities of the surviving entity, (C)
the Company sells or otherwise disposes of all or substantially all of the assets of the Company, or (D) the equity holders of
the Company transfer greater than 50% of the then issued and outstanding equity securities of Company.

 

    	 	 	 

    	 

    

 

The
Applicable Securities issued upon the exercise of the Warrants shall be subject to, and have all the benefits of, the rights,
preferences and privileges of such series of securities.

 

Exercise
of Warrants

 

The
holder of Warrants evidenced hereby may exercise them, in part or in whole, by surrendering this instrument, with the Form of
Exercise attached hereto properly completed and executed, and paying the Exercise Price. In the event that upon any exercise of
Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there
shall be issued to the holder hereof a new instrument evidencing the number of Warrants not exercised. No adjustment to the Exercise
Price will be made for any declared and unpaid dividends or distributions on any Applicable Securities issuable upon exercise
of Warrants evidenced hereby.

 

The
Company shall, to the extent necessary, issue fractional Applicable Securities upon exercise of Warrants or pay the cash equivalent
thereof, at the Company’s option.

 

Taxes
upon Exercise

 

The
Company shall pay any documentary, stamp or similar issue or transfer tax due on the issue of the Applicable Securities upon exercise
of Warrants. Nothing herein shall preclude any tax withholding required by law or regulations.

 

Company
to Provide Applicable Securities

 

Subject
to the terms and conditions of the Unit Subscription Agreement, the Company shall from time to time as may be necessary, reserve,
out of its authorized but unissued Common Stock, a sufficient number of Applicable Securities to permit the exercise of the entire
number of Warrants evidenced hereby.

 

The
certificates for Applicable Securities issued upon exercise, if any, may have notations, legends or endorsements required by law,
stock exchange rule, agreements to which the Company is subject or as the Company may deem necessary or desirable. By acceptance
of a certificate representing any Applicable Securities issued upon exercise of Warrants, the holder hereof acknowledges any restrictions
on transfer set forth on such certificate and agrees that such holder will transfer such Applicable Securities only as provided
thereon.

 

All
Applicable Securities delivered upon exercise of Warrants shall be newly issued, duly authorized, validly issued, fully paid and
non-assessable and free from any lien or adverse claim. The Company will endeavor promptly to comply with all federal and state
securities laws regulating the offer and delivery of Applicable Securities upon exercise of Warrants, if any.

 

    	 	 	 

    	 

    

 

(a)Adjustments
for Subdivisions, Combinations or Consolidations.

 

(i)Subdivisions.
In the event that the Company shall effect a subdivision of outstanding Applicable Securities, the number of Applicable Securities
issuable upon exercise of this Warrant immediately prior to such subdivision shall be proportionately increased, and the Exercise
Price in effect immediately prior to such subdivision shall concurrently with such subdivision be proportionately decreased.

 

(ii)Combinations
or Consolidations. In the event that the outstanding Applicable Securities shall be combined or consolidated, by reclassification
or otherwise, into a lesser number of Applicable Securities, the number of Applicable Securities issuable upon exercise of this
Warrant immediately prior to such combination or consolidation shall be proportionately decreased, and the Exercise Price in effect
immediately prior to such combination or consolidation shall, concurrently with the effectiveness of such combination or consolidation,
be proportionately increased.

 

(b)Adjustment
for Reclassification, Exchange or Substitution. If the Applicable Securities shall be changed into the same or a different
number of securities in any class or classes of securities, whether by capital reorganization, reclassification or otherwise (other
than a reorganization, merger, consolidation, or sale of assets provided for below), then and in each such event the holder of
each Warrant shall have the right thereafter to exercise such Warrant for the kind and amount of securities and other securities
and property receivable upon such reorganization, reclassification, or other change, by holders of the number of Applicable Securities
for which such Warrants might have been exercised immediately prior to such reorganization, reclassification or change, all subject
to further adjustment as provided herein.

 

(c)Adjustment
for Merger or Reorganization, etc. In case of any consolidation or merger of the Company with or into a corporation or another
entity or the conversion of the Company into a corporation by any other means, each Warrant shall thereafter be exercisable for
the kind and amount of equity interests or other securities or property to which a holder of the number of Applicable Securities
of the Company deliverable upon exercise of such Warrant would have been entitled upon such consolidation, merger or sale; and,
in such case, appropriate adjustment (as determined in good faith by the Board of Directors of the Company) shall be made in the
application of the provisions in this Paragraph (c) set forth with respect to the rights and interest thereafter of the holders
of the Warrants, to the end that the provisions set forth in this Section (including provisions with respect to changes in and
other adjustments of the number of Warrants evidenced hereby or the Exercise Price therefor) shall thereafter be applicable, as
nearly as reasonably may be, in relation to any equity interests or other property thereafter deliverable upon the exercise of
the Warrants.

 

(d)Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to paragraphs (a) - (d) hereof, the Company
at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each
holder of a Warrant or Warrants a certificate setting forth such adjustment or readjustment and showing in detail the facts upon
which such adjustment or readjustment is based. The Company shall, upon the written request at any time of any holder of a Warrant,
furnish or cause to be furnished to such holder a similar certificate setting forth (i) such adjustments and readjustments, (ii)
the Exercise Price then in effect, and (iii) the number of Applicable Securities and the amount, if any, of other property which
then would be received upon the exercise of such Warrant.

 

    	 	 	 

    	 

    

 

Notice
of Certain Transactions

 

In
the event that (a) the Company takes any action which would require an adjustment in the Exercise Price, (b) the Company agrees
to undertake any transaction regarding an adjustment hereunder, or (c) there is a dissolution of liquidation of the Company, then
in each case, the Company shall mail to the holder a notice stating the proposed record or effective date, as the case may be.
The Company shall mail the notice at least five days before the earlier of the proposed record date or the proposed effective
date.

 

Transferability

 

This
instrument and the Warrants may not be transferred without the prior written consent of the Company, which may be granted or withheld
in the sole and absolute discretion of the Company. Without limiting the generality of the above, the Warrants evidenced hereby
are transferable only if either (x) they first shall have been registered under the Securities Act, or (y) the Company first shall
have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or
transfer is exempt from the registration requirements of the Securities Act. Any permitted Transfer shall be effected upon surrender
of this instrument to the Company for such purpose, together with a written assignment on the Form of Assignment attached hereto,
or in other form satisfactory to the Company, duly executed by the holder hereof, together with funds to pay any transfer, documentary,
stamp or other taxes or government charges payable in connection with such transfer and any other amounts required pursuant to
this instrument. Upon the surrender of this instrument and payment as aforesaid, the Company will deliver a new instrument, in
the name of the assignee and evidencing Warrants in a permissible denomination or denominations specified in such instrument of
assignment. If less than all of the Warrants evidenced by this instrument are being transferred, the Company will deliver a new
instrument for the portion of the Warrants not being transferred.

 

No
Shareholder Rights

 

Nothing
contained in this instrument shall be construed as conferring upon the Investor or any other person the right to vote or to consent
or to receive notice as a shareholder in respect of meetings of shareholders for the election of members of the Board of Directors
of the Company or any other matters or any rights whatsoever as a shareholder of the Company; and no distributions shall be payable
or accrued in respect of this instrument or the interest represented hereby or the securities obtainable hereunder until, and
only to the extent that, the Warrants shall have been exercised.

 

    	 	 	 

    	 

    

 

Amendments

 

This
Instrument and the Warrants, or any portion thereof, may be amended or terminated, and any rights thereunder may be waived, discharged
or revised, at any time and from time to time (and any rights thereunder waived or modified) upon the written consent of the Company
and a Warrants Majority in Interest. “Warrants Majority in Interest” means the holders of warrants that were
issued pursuant to the Unit Subscription Agreement and the Offering contemplated thereunder (including the Warrants hereunder),
representing more than 50% of the equity interests that may be acquired thereunder.

 

Governing
Law; Consent to Jurisdiction

 

THIS
INSTRUMENT WILL BE INTERPRETED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE State of Texas.
The Investor hereby irrevocably consents to the exclusive jurisdiction of any state or federal court in Travis County, Texas,
and consents that all service of process be sent by nationally recognized overnight courier service directed to the Investor at
the Investor’s address set forth in the Unit Subscription Agreement and service so made will be deemed to be completed when
received by the Investor. The Investor acknowledges and agrees that the venue provided above is the most convenient forum for
both the Investor of the Company. The Investor waives any objection to venue and any objection based on a more convenient forum
in any action instituted under this instrument.

 

Waiver
of Jury Trial

 

THE
COMPANY AND THE INVESTOR, UPON RECEIPT OF THIS INSTRUMENT, IRREVOCABLY WAIVE ANY AND ALL RIGHTS THAT EACH MAY HAVE TO A TRIAL
BY JURY IN ANY ACTION, PROCEEDING OR CLAIM OF ANY NATURE RELATING TO THIS INSTRUMENT, ANY DOCUMENTS EXECUTED IN CONNECTION WITH
THIS INSTRUMENT OR ANY TRANSACTION CONTEMPLATED IN ANY OF SUCH DOCUMENTS. THE COMPANY AND INVESTOR ACKNOWLEDGE THAT THE FOREGOING
WAIVER IS KNOWING AND VOLUNTARY.

 

Miscellaneous

 

If
this instrument at any time becomes mutilated, lost, stolen or destroyed, the Company will issue, in exchange and substitution
for and upon cancellation hereof, or in lieu of and in substitution for this instrument, a new instrument of like tenor and representing
an equivalent number of Warrants, but only upon receipt of evidence satisfactory to the Company of such loss, theft or destruction
and indemnity satisfactory to it. Applicants for such substitute instrument must also comply with such other regulations and pay
such other charges as the Company may prescribe.

 

The
Company may deem and treat the holder named on the final page hereof as the absolute owner of the Warrants evidenced hereby (notwithstanding
any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, any distribution to
the holder hereof and for all other purposes, and the Company shall not be affected by any notice to the contrary.

 

[Remainder
of Page Left Intentionally Blank; Signature Page Follows]

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this instrument to be executed as of the date below.

 

	 	QUANTUM
    MATERIALS CORP.
	 	 	 
	Dated:
    March ______, 2016	 	                        
	 	By:	 
	 	Name:	 
	 	Title:	 

 

	 	investor
	 	 
	 	If
    Individual: 
	 	 
	 	Investor:	 
	 	 
	 	Investor
    Address: 	 
	 	 	 
	 	 
	 	If
    Entity:
	 	 
	 	 
	 	Name
    of Entity
	 	 
	 	By:	
	 	Name:	
	 	Title:
    	
	 	 
	 	Investor
    Address: 	 
	 	 	 

 

    	 	 	 

    	 

    

 

FORM
OF EXERCISE

 

(To
be executed upon exercise of Warrants)

 

The
undersigned hereby irrevocably elects to exercise the right to purchase __________ Applicable Securities of the Company (or such
other securities or assets of the Company as are purchasable in their place), and herewith tenders payment for such Securities
(or other securities or assets) to Quantum Materials Corp. (the “Company”) by delivery to the Company of the
Exercise Price. The undersigned requests that a certificate for such Applicable Securities (or other securities) be registered
in the name of

 

	 		 	Name
	 		 	Address
	 		 	Social
    Security or Taxpayer Identification Number

 

and,
if less than all Warrants represented by this Warrant are being exercised, that a new instrument representing the remaining balance
of Warrants be issued in the name of

 

	 	 	 	Name
	 	 	 	Address
	 	 	 	Social
    Security or Taxpayer Identification Number

 

IN
THE ABSENCE OF ANY SPECIFICATION REQUIRED ABOVE, APPLICABLE SECURITIES (or such other
securities or assets of the Company as are purchasable in their place) AND ANY NEW WARRANT INSTRUMENT, AS THE CASE MAY
BE, WILL BE REGISTERED OR MADE TO THE HOLDER AT THE ADDRESS FOR SUCH HOLDER AS TO WHICH THE COMPANY HAS BEEN NOTIFIED.

 

	Date:
    	 	 	Signature:	 

 

Note:
Any transfer of the Warrants is subject to the prior written consent of the Company, subject to its sole and absolute discretion.

 

    	 	 	 

    	 

    

 

[FORM
OF ASSIGNMENT]

 

(To
be executed to transfer the Warrants)

 

FOR
VALUE RECEIVED, _________________________________ the undersigned hereby sells, assigns and transfers unto

 

	 	 	 	Name
	 	 	 	Address
	 	 	 	Social
    Security or Taxpayer Identification Number

 

 

___________
Warrants to purchase Applicable Securities (or such other securities or assets of the Company as are purchasable in their place)
of the within-named Company, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint
, Attorney, to transfer such Warrants on the books of the within-named Company, with full power of substitution. The holder hereby
represents and warrants to the Company that the transfer represented hereby is being made in accordance with the terms of the
instrument evidencing the Warrants.

 

	Date
    	 	 	Signature:SECURITIES
PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of the ____ day of ____________, 2016
(the “Effective Date”) by and between QUANTUM MATERIALS CORP., a Nevada corporation (the “Company”),
and _________________ (the “Investor”).

 

WHEREAS,
pursuant to that certain Private Placement Memorandum of the Company, dated March 2016, the Company is offering for sale (the
“Offering”) 3,000 units of the Company (each, a “Unit”, and together with
each other Unit issued pursuant to the Offering, the “Units”), each consisting of (a) a $1,000 Unsecured
Convertible Promissory Note (the “Note,” and together with each other Note issued pursuant to the Offering,
the “Notes”), which Note shall be convertible into Common Shares (as defined below) (as converted, collectively,
the “Conversion Shares”), at a conversion price of $0.12 per share, subject to adjustment, in accordance
with the terms of the Note, and (b) a warrant (the “Warrant,” and together with each other Warrant issued
pursuant to the Offering, the “Warrants”) to purchase 4,166 Common Shares (as exercised, collectively,
the “Warrant Shares”), at an exercise price of $0.15 per Warrant Share, subject to adjustment, in accordance
with the terms of the Warrant.

 

WHEREAS,
upon the terms and condition stated in the Agreement and pursuant to Section 4(a)(2) of the 1933 Act (as defined below) and Rule
506 of Regulation D promulgated thereunder, the Investor wishes to purchase from the Company, and the Company wishes to sell to
the Investor, ____ Units in the Offering for an aggregate purchase price of $___________; and

 

WHEREAS,
the Units, the Notes, the Conversion Shares, the Warrants and the Warrant Shares, are collectively referred to herein as the “Securities”.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration
of the premises and the mutual agreements, representations and warranties, provisions and covenants contained herein, the parties
hereto, intending to be legally bound hereby, agree as follows:

 

1.       Purchase
and Sale of Units. On the Closing Date (as hereinafter defined), subject to the terms and conditions of this Agreement, the
Investor hereby agrees to purchase from the Company, and the Company hereby agrees to sell and issue to the Investor, ____ Units.

 

2.       Purchase
Price. The aggregate purchase price for the Units to be purchased by the Investor at the Closing shall be $_____________ (the
“Purchase Price”). At the Closing, the Investor shall fund the Purchase Price by wire transfer of immediately
available funds to the account specified in writing by the Company prior to the Effective Date.

 

3.       The
Closing. Subject to the conditions set forth below, the purchase and sale of the Units shall take place at the offices of
_______________________, on the Effective Date (the “Closing” and the “Closing Date”).
At the Closing, the Company shall deliver to the Investor: (i) this Agreement duly executed by the Company, (ii) the Notes contained
in the Units purchased hereby duly executed by the Company and registered in the name of the Investor, and (iii) the Warrants
contained in the Units purchased hereby duly executed by the Company and registered in the name of the Investor. At the Closing,
the Investor shall deliver to the Company (x) this Agreement duly executed by the Investor, (y) the Purchase Price for the Units
purchased hereunder, and (z) the completed Investor Questionnaire attached as Exhibit C.

 

    	 

    	 

    

 

4.       Closing
Conditions; Certain Covenants. 

 

4.1       Conditions
to the Investor’s Obligations. The obligation of the Investor to purchase the Units to be issued to the Investor at
the Closing is subject to the fulfillment, to the Investor’s reasonable satisfaction, prior to or at the Closing, of each
of the following conditions:

 

(a)       Representations
and Warranties. The representations and warranties of the Company contained in this Agreement shall be true and correct in
all respects on the Effective Date (except for representations and warranties that speak as of a specific date, which shall be
true and correct as of such specific date).

 

(b)       Covenants.
The Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required
to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

 

(c)       Notes
and Warrants. At the Closing, the Company shall have duly executed and delivered to the Investor the Notes and Warrants comprising
the Units purchased hereby, in each case duly executed by the Company and registered in the name of the Investor.

 

(d)       No
Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain substantial damages
in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(e)       Proceedings
and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident
to such transactions shall be reasonably satisfactory in substance and form to the Investor, and the Investor shall have received
all such counterpart originals or certified or other copies of such documents as it may reasonably request.

 

(f)       No
Consents. The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary
for the sale of the Securities.

 

4.2       Conditions
to the Company’s Obligations. The obligation of the Company to sell and issue the Units to the Investor at the Closing
is subject to the fulfillment, to the Company’s reasonable satisfaction, prior to or at the Closing, of each of the following
conditions:

 

(a)       Representations
and Warranties. The representations and warranties of the Investor contained in this Agreement shall be true and correct in
all respects on the Effective Date (except for representations and warranties that speak as of a specific date, which shall be
true and correct as of such specific date).

 

(b)       Purchase
Price. At the Closing, the Investor shall have tendered to the Company the Purchase Price by wire transfer of immediately
available funds to the account specified in writing by the Company prior to the Effective Date.

 

    	2

    	 

    

 

(c)       No
Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial damages
in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(d)       Proceedings
and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident
to such transactions shall be satisfactory in substance and form to the Company and the Company shall have received all such counterpart
originals or certified or other copies of such documents as the Company may reasonably request.

 

4.3       Securities
Law Disclosure; Publicity. The Company shall, by 8:00 a.m. (Chicago time) on or before the fourth (4th) business
day immediately following the Effective Date, issue a Current Report on Form 8-K disclosing the material terms of the transactions
contemplated hereby, and including the form of this Agreement as an exhibit thereto (the “Current Report”).
From and after the issuance of the Current Report, the Company represents to the Investor that the Company shall have publicly
disclosed all material, non-public information delivered to the Investor by the Company or any of its Subsidiaries, or any of
their respective officers, directors, employees or agents in connection with the transactions contemplated by this Agreement.
In addition, effective upon the filing of the Current Report, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, affiliates, employees or agents, on the one hand, and the Investor or any of its affiliates, on
the other hand, shall terminate. The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and
their respective officers, directors, employees and agents not to, provide the Investor with any material, non-public information
regarding the Company or any of its Subsidiaries from and after the Effective Date without the express prior written consent of
the Investor (which may be granted or withheld in the Investor’s sole discretion). To the extent that the Company or any
Person acting on its behalf delivers any material, non-public information to the Investor (as determined in the reasonable good
faith judgment of the Investor) without the Investor’s consent, (i) the Company hereby covenants and agrees that the Investor
shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public
information, and (ii) in addition to any other remedy provided herein or in the Note or Warrant, the Investor shall have the right
to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information
without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes
it has received information that constitutes material, non-public information, the Company shall have at least 24 hours to publicly
disclose such material, non-public information prior to any such disclosure by the Investor, and the Company shall have failed
to publicly disclose such material, non-public information within such time period. The Company shall afford the Investor and
its counsel with a reasonable opportunity to review and comment upon, shall consult with the Investor and its counsel on the form
and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release,
Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor, its purchases hereunder
or any aspect of this Agreement or the transactions contemplated hereby, prior to the issuance, filing or public disclosure thereof,
and the Company shall not issue, file or publicly disclose any such information to which the Investor shall object. For the avoidance
of doubt, the Company shall not be required to submit for review any such disclosure contained in periodic reports filed with
the Commission under the Exchange Act if it shall have previously provided the same disclosure for review in connection with a
previous filing.

 

    	3

    	 

    

 

4.4       Legends.
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Securities other than pursuant to an effective registration statement or Rule 144 (as defined below), to the Company or to
an affiliate of the Investor, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected
by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Securities under the 1933 Act.
The Investor understands that the Securities, except as set forth below, shall bear any legends as required by applicable state
securities or “Blue Sky” laws in addition to a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of such stock certificates):

 

[NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE]
[EXERCISABLE] HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE
FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.

 

The
Company shall use its reasonable best efforts to cause its transfer agent to remove the legend set forth above and to issue a
certificate without such legend to the holder of the Securities upon which it is stamped, or to issue to such holder by electronic
delivery at the applicable balance account at the Depository Trust Company (“DTC”), unless otherwise
required by state securities or “blue sky” laws, at such time as (i) such Securities are registered for resale under
the 1933 Act, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of
counsel, in a form generally acceptable to the Company’s legal counsel, to the effect that such sale, assignment or transfer
of the Securities may be made without registration under the 1933 Act, or (iii) such holder provides the Company and its legal
counsel with reasonable assurance in writing that the Securities can be sold, assigned or transferred pursuant to Rule 144 or
Rule 144A. In furtherance of the foregoing, the Company agrees that, following the effective date of a registration statement
covering the resale of such Securities or at such time as such legend is not required pursuant to this Section 4.4, the Company
shall, no later than three Trading Days following the delivery by the Investor to the Company or the Company’s transfer
agent of a certificate representing the Conversion Shares or Warrant Shares, as applicable, issued with a restrictive legend (such
third Trading Day, the “Legend Removal Date”), either: (A) issue and deliver (or cause to be issued
and delivered) to the Investor a certificate representing such Conversion Shares or Warrant Shares, as applicable, that is free
from all restrictive and other legends or (B) cause the Company’s transfer agent to credit the Investor’s or its designee’s
account at DTC through its Deposit/Withdrawal at Custodian (DWAC) system with a number of Common Shares equal to the number of
Conversion Shares or Warrant Shares, as applicable represented by the certificate so delivered by the Investor. If the Company
fails on or prior to the Legend Removal Date to either (i) issue and deliver (or cause to be issued and delivered) to the Investor
a certificate representing the Conversion Shares or Warrant Shares, as applicable, that is free from all restrictive and other
legends or (ii) cause the Company’s transfer agent to credit the balance account of the Investor or its designee at DTC
through its Deposit/Withdrawal at Custodian (DWAC) system with a number of Common Shares equal to the number of Conversion Shares
or Warrant Shares, as applicable, represented by the certificate delivered by the Investor pursuant hereto, then, in addition
to all other remedies available to the Investor, the Company shall pay in cash to the Investor on each day after the Legend Removal
Date that the issuance or credit of such shares is not timely effected an amount equal to 1.0% of the product of (A) the sum of
the number of Conversion Shares or Warrant Shares, as applicable, not issued to the Investor on a timely basis and to which the
Investor is entitled and (B) the VWAP for the five Trading Day period immediately preceding the Legend Removal Date. In addition
to the foregoing, if the Company fails to so properly deliver such unlegended certificates or so properly credit the account of
the Investor or its designee at DTC by the Legend Removal Date, and if on or after the Legend Removal Date the Investor purchases
(in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Investor of Conversion
Shares or Warrant Shares that the Investor anticipated receiving from the Company without any restrictive legend, then the Company
shall, within three Trading Days after the Investor’s request, pay cash to the Investor in an amount equal to the Investor’s
total purchase price (including brokerage commissions, if any) for the Common Shares so purchased, at which point the Company’s
obligation to deliver a certificate or credit the Investor’s or its designee’s account at DTC for such Conversion
Shares or Warrant Shares shall terminate and such shares shall be cancelled.

 

    	4

    	 

    

 

5.       Representations
and Warranties of the Company. Except as set forth in the Disclosure Schedules or the Public Reports (as defined herein),
which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the
extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following
representations and warranties to the Investors:

 

5.1       Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Nevada. The Company is duly qualified to transact business and is in good standing in each jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.

 

5.2       Capitalization
and Voting Rights. The authorized capital stock of the Company and the shares thereof issued and outstanding were as set forth
in the Public Reports (as defined in Section 5.6 hereof) as of the dates reflected therein. As of the Effective Date, there are
_________ Common Shares issued and outstanding. All of the outstanding Common Shares have been duly authorized and validly issued,
and are fully paid and nonassessable. Except as set forth in the Public Reports and this Agreement, there are no agreements or
arrangements under which the Company is obligated to register the sale of any securities under the Securities Act. Except as set
forth in the Public Reports, no Common Shares are entitled to preemptive rights and there are no outstanding debt securities and
no contracts, commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares
of the capital stock of the Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company
other than those issued or granted in the ordinary course of business pursuant to the Company’s equity incentive and/or
compensatory plans or arrangements. Except for customary transfer restrictions contained in agreements entered into by the Company
to sell restricted securities or as set forth in the Public Reports, the Company is not a party to, and it has no knowledge of,
any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except as set forth in the
Public Reports, the offer and sale of all capital stock, convertible or exchangeable securities, rights, warrants or options of
the Company issued prior to the Closing Date complied with all applicable federal and state securities laws, and no stockholder
has any right of rescission or damages or any “put” or similar right with respect thereto that would have a Material
Adverse Effect. Except as set forth in the Public Reports, there are no securities or instruments containing anti-dilution or
similar provisions that will be triggered by the issuance of the Securities or this Agreement or the consummation of the transactions
described herein or therein.

 

5.3       Authorization;
Enforcement. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization,
execution and delivery of this Agreement, and the Notes and the Warrants comprising the Units, and the performance of all obligations
of the Company, and the authorization (or reservation for issuance), sale and issuance of Units, the Notes contained in the Units,
the Warrant contained in the Units, the Conversion Shares and the Warrant Shares, have been taken on or prior to the Effective
Date. Each of this Agreement, and the Notes and the Warrants comprising the Units has been duly executed by the Company and, when
delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

    	5

    	 

    

 

5.4       Valid
Issuance of the Securities; Reservation of Common Shares. The Notes and the Warrants comprising the Units are duly authorized
and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, and free and clear of all Liens
imposed by the Company other than restrictions on transfer under this Agreement and under applicable state and federal securities
laws. The Conversion Shares when issued and delivered in accordance with the terms of this Agreement and the Notes contained in
the Units for the consideration expressed herein and therein, will be duly and validly issued, fully paid and non-assessable and
free and clear of all Liens imposed by the Company other than restrictions on transfer under this Agreement and under applicable
state and federal securities laws. The Warrant Shares when issued and delivered in accordance with the terms of this Agreement
and the Warrants contained in the Units for the consideration expressed herein and therein, will be duly and validly issued, fully
paid and non-assessable and free and clear of all Liens imposed by the Company other than restrictions on transfer under this
Agreement and under applicable state and federal securities laws. As of the Closing, the Company has reserved from its duly authorized
capital stock not less than 100% of the sum of (i) the maximum number of Conversion Shares issuable upon conversion of the Notes
contained in the Units (assuming for purposes hereof that the Notes are convertible at the initial Conversion Price (as defined
in the Notes) and without taking into account any limitations on the conversion of the Notes set forth therein) and (ii) the maximum
number of Warrant Shares issuable upon exercise of the Warrants contained in the Units (without taking into account any limitations
on the exercise of the Warrants set forth therein).

 

5.5       Offering.
Subject to the truth and accuracy of the Investor’s representations set forth in Section 6 of this Agreement, the offer
and sale of the Securities, as contemplated by this Agreement are exempt from the registration requirements of the Securities
Act of 1933, as amended (the “1933 Act”), and the qualification or registration requirements of state
securities laws or other applicable blue sky laws. Neither the Company nor any authorized agent acting on its behalf will take
any action hereafter that would cause the loss of such exemptions.

 

5.6       Public
Reports. The Company is current in its filing obligations under the 1934 Act, including without limitation as to its filings
of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (collectively, the “Public
Reports”). The Public Reports do not contain any untrue statement of a material fact or omit to state any fact necessary
to make any statement therein not misleading. The financial statements included within Company’s Annual Report on Form 10-K
for the year ended June 30, 2015, as amended, and for each quarterly period thereafter (the “Financial Statements”)
have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a
consistent basis throughout the periods indicated and with each other, except that unaudited Financial Statements may not contain
all footnotes required by generally accepted accounting principles. The Financial Statements fairly present, in all material respects,
the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject
in the case of unaudited Financial Statements to normal year-end audit adjustments.

 

5.7       Compliance
With Laws. The Company has not violated any law or any governmental regulation or requirement which violation has had or would
reasonably be expected to have a Material Adverse Effect on its business and the Company has not received written notice of any
such violation. The Company is not in violation of the requirements of the Trading Market and has no knowledge of any facts or
circumstances which could reasonably lead to delisting or suspension of the Common Shares in the foreseeable future.

 

5.8       Violations.
The consummation of the transactions contemplated by this Agreement and all other documents and instruments required to be
delivered in connection therewith will not result in or constitute any of the following: (a) a violation of any provision of the
articles of incorporation, bylaws or other governing documents of the Company; (b) a violation of any provisions of any applicable
law or of any writ or decree of any court or governmental instrumentality; (c) a default or an event that, with notice or lapse
of time or both, would be a default, breach, or violation of a lease, license, promissory notes, conditional sales contract, commitment,
indenture, mortgage, deed of trust, or other agreement, instrument, or arrangement to which the Company is a party or by which
the Company or its property is bound; (d) an event that would permit any party to terminate any agreement or to accelerate the
maturity of any indebtedness or other obligation of the Company; or (e) the creation or imposition of any lien, pledge, option,
security agreement, equity, claim, charge, encumbrance or other restriction or limitation on the capital stock or on any of the
properties or assets of the Company.

 

    	6

    	 

    

 

5.9       Consents;
Waivers. No consent, waiver, approval or authority of any nature, or other formal action, by any Person, or any agency, bureau
or department of any government or any subdivision thereof, not already obtained, is required in connection with the execution
and delivery of this Agreement by the Company or the consummation by the Company of the transactions provided for herein.

 

5.10       Sarbanes-Oxley
Act. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective
as of the Effective Date, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective
as of the Effective Date.

 

5.11       Absence
of Litigation. Except as disclosed in the Company’s Public Reports, there is no action, suit, proceeding, inquiry or
investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the
knowledge of the Company, threatened against or affecting the Company, the Common Shares or any of the Company’s officers
or directors in their capacities as such.

 

5.12       Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the Public Reports, except as specifically disclosed in a subsequent Public Report filed prior to the Effective Date: (i)
there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued
expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected
in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other
property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing Company
stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, properties, operations, assets or financial condition, that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least one Trading Day prior to the date that this representation is made.

 

    	7

    	 

    

 

5.13       Intellectual
Property. The Company has, or has rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
as described in the Public Reports as necessary or required for use in connection with their respective businesses and which the
failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”).
The Company has not received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated
or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.
The Company has not received, since the date of the latest audited financial statements included within the Public Reports, a
written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights
of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the
Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

5.14       Registration
Rights. No Person has any right to cause the Company to effect the registration under the 1933 Act of any securities of the
Company.

 

5.15       Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the
Investor will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Investor regarding the Company and its Subsidiaries, their respective businesses
and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company
during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that the Investor
does not make nor has made any representations or warranties with respect to the transactions contemplated hereby other than those
specifically set forth in Section 6 hereof.

 

5.16       No
Integrated Offering. Assuming the accuracy of the Investor’s representations and warranties set forth in Section 6,
neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of (i) the 1933 Act which would require the
registration of any such securities under the 1933 Act, or (ii) any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.

 

    	8

    	 

    

 

5.17       No
General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates, nor any
Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any
placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by the Investor)
relating to or arising out of the transactions contemplated hereby. Neither the Company nor any of its Subsidiaries has engaged
any placement agent or other agent in connection with the offer or sale of the Securities.

 

5.18       Bankruptcy
Status; Indebtedness. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any
law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company
or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary
bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. Schedule 5.18 sets
forth as of the Effective Date all outstanding secured and unsecured Indebtedness (as defined below) of the Company or any of
its Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed (other than trade accounts payable incurred in the ordinary course
of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether
or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (z) the present value of any lease payments due under leases required to be capitalized in accordance with GAAP. The Company
is not in default with respect to any Indebtedness. The Company and its Subsidiaries, individually and on a consolidated basis,
are not, and after giving effect to the transactions contemplated hereby to occur at the Closing will not be, Insolvent (as defined
below). “Insolvent” means, (I) with respect to the Company and its Subsidiaries, on a consolidated basis,
(i) the present fair saleable value of the Company’s and its Subsidiaries’ assets is less than the amount required
to pay the Company’s and its Subsidiaries’ total Indebtedness (as defined below), (ii) the Company and its Subsidiaries
are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute
and matured or (iii) the Company and its Subsidiaries intend to incur or believe that they will incur debts that would be beyond
their ability to pay as such debts mature; and (II) with respect to the Company and each Subsidiary, individually, (i) the present
fair saleable value of the Company’s or such Subsidiary’s (as the case may be) assets is less than the amount required
to pay its respective total Indebtedness, (ii) the Company or such Subsidiary (as the case may be) is unable to pay its respective
debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (iii)
the Company or such Subsidiary (as the case may be) intends to incur or believes that it will incur debts that would be beyond
its respective ability to pay as such debts mature. Neither the Company nor any of its Subsidiaries has engaged in any business
or in any transaction, and is not about to engage in any business or in any transaction, for which the Company’s or such
Subsidiary’s remaining assets constitute unreasonably small capital.

 

    	9

    	 

    

 

5.19       Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting
purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase
any other securities of the Company.

 

5.20       Acknowledgment
Regarding Investor’s Purchase of Securities. The Company acknowledges and agrees that the Investor is acting solely in
the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby and that
the Investor is not (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” (as
defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of
more than 10% of the Common Shares (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges that
the Investor is not acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity)
with respect to this Agreement and the transactions contemplated hereby, and any advice given by the Investor or any of its representatives
or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental to the Investor’s
purchase of the Securities. The Company further represents to the Investor that the Company’s decision to enter into this
Agreement has been based solely on the independent evaluation by the Company and its representatives.

 

5.21       Shell
Company Status. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the Securities
Act.

 

5.22       Dilutive
Effect. The Company understands and acknowledges that the number of Conversion Shares and Warrant Shares will increase in
certain circumstances. The Company further acknowledges that its obligation to issue the Conversion Shares upon conversion of
the Notes contained in the Units and the Warrant Shares upon exercise of the Warrants contained in the Units in accordance with
this Agreement, the Notes and the Warrants is absolute and unconditional, regardless of the dilutive effect that such issuance
may have on the ownership interests of other stockholders of the Company.

 

5.23       Application
of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including,
without limitation, any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover provision
under the articles of incorporation, bylaws or other organizational documents or the laws of the jurisdiction of its incorporation
or otherwise which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement,
including, without limitation, the Company’s issuance of the Securities and the Investor’s ownership of the Securities.
The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any stockholder
rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Shares or a change in control of
the Company or any of its Subsidiaries.

 

    	10

    	 

    

 

5.24       Insurance.
The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
as management of the Company believes to be prudent and customary in the business in which the Company is engaged. The Company
has not been refused any insurance coverage sought or applied for, and the Company has no reason to believe that it will be unable
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

5.25       Employee
Relations. The Company is not a party to any collective bargaining agreement and does not employ any member of a union. The
Company believes that its relations with its employees are good. No executive officer (as defined in Rule 501(f) promulgated under
the 1933 Act) or other key employee of the Company has notified the Company that such officer intends to leave the Company or
otherwise terminate such officer’s employment with the Company. No executive officer or other key employee of the Company
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued
employment of each such executive officer or other key employee (as the case may be) does not subject the Company to any liability
with respect to any of the foregoing matters. The Company is in compliance with all federal, state, local and foreign laws and
regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and
hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to
result in a Material Adverse Effect.

 

5.26       Title.
The Company and its Subsidiaries have good and marketable title in fee simple to all real property, and have good and marketable
title to all personal property, owned by them which is material to the business of the Company and its Subsidiaries, in each case,
free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do
not interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries. Any real
property and facilities held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of
such property and buildings by the Company or any of its Subsidiaries.

 

5.27       Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with all Environmental Laws (as defined below), (ii) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing
clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate,
a Material Adverse Effect. “Environmental Laws” means all federal, state, local or foreign laws relating
to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened
releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous
Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand
letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated
or approved thereunder.

 

    	11

    	 

    

 

5.28       Tax
Status. The Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state income and all
other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate
for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of
the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify
as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”).

 

5.29       Transfer
Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be
paid in connection with the issuance, sale and transfer of the Securities to be sold to the Investor hereunder will be, or will
have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

5.30       Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries nor any director, officer, agent, employee or other Person
acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company
or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official
or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act
of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to
any foreign or domestic government official or employee.

 

5.31       Illegal
or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the best of the
Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees,
agents or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which
the Company or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment,
contribution or gift of money, property, or services, whether or not in contravention of applicable law, (a) as a kickback or
bribe to any Person or (b) to any political organization, or the holder of or any aspirant to any elective or appointive public
office except for personal political contributions not involving the direct or indirect use of funds of the Company or any of
its Subsidiaries.

 

5.32       Money
Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation,
the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
without limitation, (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

    	12

    	 

    

 

5.33       Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment
company,” an affiliate of an “investment company,” a company controlled by an “investment company”
or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

5.34       U.S.
Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any
of the Securities are held by the Investor, shall become, a U.S. real property holding corporation within the meaning of Section
897 of the Code, and the Company and each Subsidiary shall so certify upon the Investor’s request.

 

5.35       No
Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”)
is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act
(a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3)
under the 1933 Act. The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event.

 

5.36       Ranking
of Note. The Notes shall be treated on a parri passu basis. All payments shall be made on a pro rata basis,
based upon the outstanding principal balance of the Notes. No other Indebtedness of the Company, at the Closing, will be senior
to, or pari passu with, the Notes in right of payment, whether with respect to payment or redemptions, interest, damages,
upon liquidation or dissolution or otherwise.

 

6.       Representations
and Warranties of the Investor. The Investor hereby represents, warrants and covenants that:

 

6.1       Authorization.
The Investor has full power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery of this Agreement,
the performance of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby.

 

6.2       No
Public Sale or Distribution. The Investor is (i) acquiring the Units, and the Notes and Warrants comprising the Units, (ii)
upon conversion of the Notes contained in the Units will acquire the Conversion Shares, and (iii) upon exercise of the Warrants
contained in the Units will acquire the Warrant Shares, in each case for its own account, not as a nominee or agent, and not with
a view towards, or for resale in connection with, the public sale or distribution of any part thereof, except pursuant to sales
registered or exempted under the 1933 Act. The Investor is acquiring the Securities hereunder in the ordinary course of its business.
The Investor does not presently have any contract, agreement, undertaking, arrangement or understanding, directly or indirectly,
with any individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
and a government or any department or agency thereof (a “Person”) to sell, transfer, pledge, assign
or otherwise distribute any of the Securities.

 

    	13

    	 

    

 

6.3       Accredited
Investor Status; Investment Experience. The Investor is an “accredited investor” as that term is defined in Rule
501(a) of Regulation D. The Investor can bear the economic risk of its investment in the Securities, and has such knowledge and
experience in financial and business matters that it is capable of evaluating the merits and risks of an investment in the Securities.
The Investor covenants and agrees to, simultaneously with the Investor’s execution and delivery of this Agreement, complete
and deliver the Investor Questionnaire set forth on Exhibit C hereto.

 

6.4       Reliance
on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part
upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility
of the Investor to acquire the Securities.

 

6.5       Information.
The Investor and its advisors, if any, have been furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Securities which have been requested by the Investor. The Investor
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other
due diligence investigations conducted by the Investor or its advisors, if any, or its representatives shall modify, amend or
affect the Investor’s right to rely on the Company’s representations and warranties contained herein. The Investor
understands that its investment in the Securities involves a high degree of risk. The Investor has sought such accounting, legal
and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.
The Investor is relying solely on its own accounting, legal and tax advisors, and not on any statements of the Company or any
of its agents or representatives, for such accounting, legal and tax advice with respect to its acquisition of the Securities
and the transactions contemplated by this Agreement.

 

6.6       No
Governmental Review. The Investor understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

    	14

    	 

    

 

6.7       Validity;
Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor
and shall constitute the legal, valid and binding obligation of the Investor enforceable against the Investor in accordance with
its terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies. The execution, delivery and performance by the Investor of this Agreement and the consummation
by the Investor of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of
the Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or
decree (including federal and state securities or “Blue Sky” laws) applicable to the Investor, except in the case
of clause (ii) above, for such conflicts, defaults or rights which would not, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the ability of the Investor to perform its obligations hereunder.

 

6.8       Organization
and Standing. The Investor is a limited liability company duly organized, validly existing and in good standing under the
laws of the State of Illinois.

 

6.9       Certain
Transactions. The Investor has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with the Investor, engaged in any transactions in the securities of the Company (including, without limitations, any Short Sales
involving the Company’s securities) since the earlier to occur of (i) the time that the Investor was first contacted by
the Company, Roth Capital Partners, LLC, or any other person regarding an investment in the Company and (ii) the thirtieth (30th)
day prior to the date of this Agreement. The Investor covenants that neither it nor any person acting on its behalf or pursuant
to any understanding with it will engage in any transactions in the securities of the Company (including Short Sales) prior to
the time that the transactions contemplated by this Agreement are publicly disclosed. For purposes hereof, “Short
Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the 1934 Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short
sales, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-US broker
dealers or foreign regulated brokers.

 

7.       Use
of Proceeds. The Company shall use the proceeds from the sale of the Securities solely for general working capital purposes.

 

8.       Rule
144 Availability; Public Information. At all times during the period commencing on the Closing Date and ending at such time
that all of the Securities can be sold without the requirement to be in compliance with Rule 144(c)(1) under the 1933 Act and
otherwise without restriction or limitation pursuant to Rule 144 under the 1933 Act, the Company shall use its reasonable best
efforts to ensure the availability of Rule 144 under the 1933 Act to the Investor with regard to the Conversion Shares and the
Warrant Shares, including compliance with Rule 144(c)(1) under the 1933 Act. If, (i) at any time the Investor owns any Securities,
the Company shall fail for any reason to satisfy the current public information requirement under Rule 144(c) under the 1933 Act
(a “Public Information Failure”), or (ii) the Company shall fail to take such action as is reasonably
requested by the Investor to enable the Investor to sell the Conversion Shares and the Warrant Shares pursuant to Rule 144 under
the 1933 Act (including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions
to the Company’s transfer agent as may be reasonably requested from time to time by the Investor and otherwise fully cooperate
with Investor and Investor’s broker to effect such sale of securities pursuant to Rule 144 under the 1933 Act), then, in
either case, in addition to the Investor’s other available remedies, the Company shall pay to a Investor, in cash, as liquidated
damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in
cash equal to one percent (1.0%) of the aggregate Purchase Price of the Investor’s Securities on the day of a Public Information
Failure and on every thirtieth (30th) day (pro rated for periods totaling less than thirty days) thereafter until the earlier
of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required
for the Investor to transfer the Conversion Shares or the Warrant Shares pursuant to Rule 144 under the 1933 Act. The payments
to which the Investor shall be entitled pursuant to this Section 8 are referred to herein as “Rule 144 Failure Payments.”
Rule 144 Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Rule 144 Failure
Payments are incurred and (ii) the third (3rd) Trading Day after the event or failure giving rise to the Rule 144 Failure Payments
is cured.

 

    	15

    	 

    

 

9.       Indemnification.
In consideration of the Investor’s execution and delivery of this Agreement and acquiring the Securities hereunder and
in addition to all of the Company’s other obligations under this Agreement, and the Notes and the Warrants comprising the
Units, the Company shall defend, protect, indemnify and hold harmless the Investor and each holder of any Securities and all of
their stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing
Persons’ agents or other representatives (including, without limitation, those retained in connection with the transactions
contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions,
causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith
(irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including
reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any
Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty
made by the Company in this Agreement, the Notes contained in the Units or the Warrants contained in the Units, (b) any breach
of any covenant, agreement or obligation of the Company contained in any of this Agreement, the Notes contained in the Units or
the Warrants contained in the Units, or (c) any cause of action, suit, proceeding or claim brought or made against such Indemnitee
by a third party (including for these purposes a derivative action brought on behalf of the Company or any Subsidiary) or which
otherwise involves such Indemnitee that arises out of or results from (i) the execution, delivery, performance or enforcement
of any of this Agreement, the Notes contained in the Units or the Warrants contained in the Units, (ii) any transaction financed
or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (iii) the
status of the Investor or holder of the Securities either as an investor in the Company pursuant to the transactions contemplated
by this Agreement or as a party to this Agreement (including, without limitation, as a party in interest or otherwise in any action
or proceeding for injunctive or other equitable relief). To the extent that the foregoing undertaking by the Company may be unenforceable
for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
which is permissible under applicable law.

 

10.       Registration
of Conversion Shares and Warrant Shares. If the Company proposes to file a registration statement with the Commission with
respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible
into, equity securities, for its own account or for the account of any stockholder of the Company (other than (i) any registration
statement relating to any “equity-line” or similar transaction, (ii) a registration statement on Form S-4 or Form
S-8 or their successors or any other form for a limited similar purpose or (iii) any registration statement covering only securities
proposed to be issued in exchange for securities or assets of another person), the Company shall, at least thirty (30) days prior
to such filing, give written notice to the Investor of its intention to do so and, upon the written request of the Investor given
within twenty (20) days of the receipt of such notice (which request shall state the intended method of disposition of the Registrable
Securities held by the Investor), the Company shall use its reasonable best efforts to cause the Registrable Securities that the
Investor requests the Company to register for resale to be included in such registration and shall use its best efforts to cause
the managing underwriter or underwriters (if any) of a proposed underwritten offering to permit such Registrable Securities to
be included in such registration on the same terms and conditions as any similar securities of the Company, in each case to the
extent necessary to permit the resale of such Registrable Securities by the Investor under Rule 415 under the Securities Act at
then prevailing market prices (and not fixed prices) in accordance with the intended methods of distribution specified in the
request of the Investor. The Investor and its counsel shall have a reasonable opportunity to review and comment upon such registration
statement and any amendment or supplement to such registration statement and any related prospectus prior to its filing with the
Commission, and the Company shall give due consideration to all such comments. The Investor shall furnish all information reasonably
requested by the Company for inclusion therein. The Company shall use its reasonable best efforts to have the registration statement
and any amendment declared effective by the Commission at the earliest possible date. The Company shall use reasonable best efforts
to keep the registration statement effective pursuant to Rule 415 promulgated under the Securities Act and available for resales
of all of the Registrable Securities at all times until the earlier of (i) the date as of which the Investor may resell all of
the Registrable Securities without restriction pursuant to the last sentence of Rule 144(b)(1)(i) promulgated under the Securities
Act (or successor thereto) or (ii) the date on which the Investor shall have resold all the Registrable Securities. The registration
statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein,
in light of the circumstances in which they were made, not misleading.

 

    	16

    	 

    

 

11.       Listing;
Blue Sky. The Company shall promptly secure the approval for listing of (i) the maximum number of Conversion Shares issuable
upon conversion of the Notes contained in the Units purchased hereby (without taking into account any limitations on the conversion
of the Notes set forth therein) that may from time to time be issuable under the terms of the Notes contained in the Units purchased
hereby and (ii) the maximum number of Warrant Shares issuable upon exercise of the Warrants contained in the Units purchased hereby
(without taking into account any limitations on the exercise of the Warrants set forth therein) that may from time to time be
issuable under the terms of the Warrants contained in the Units purchased hereby, in each case on the Trading Market, if required
by the Trading Market. The Company shall not take any action which could be reasonably expected to result in the delisting or
suspension of the quotation of the Common Shares on the Trading Market. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Investor
at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United
States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Investor
on or prior to the Closing Date. Without limiting any other obligation of the Company under this Agreement, the Company shall
timely make all filings and reports relating to the offer and sale of the Securities required under all applicable securities
laws (including, without limitation, all applicable federal securities laws and all applicable “Blue Sky” laws), and
the Company shall comply with all applicable federal, foreign, state and local laws, statutes, rules, regulations and the like
relating to the offering and sale of the Securities to the Investor. The Company shall pay all fees and expenses in connection
with satisfying its obligations under this Section 11.

 

12.       Reservation
of Shares. So long as any of the Notes or Warrants contained in the Units purchased hereby remain outstanding, the Company
shall take all action necessary to at all times have authorized and reserved for the purpose of issuance not less than 100% of
the sum of (i) the maximum number of Conversion Shares issuable upon conversion of the Notes contained in the Units purchased
hereby (without taking into account any limitations on the conversion of the Notes set forth therein) and (ii) the maximum number
of Warrant Shares issuable upon exercise of the Warrants contained in the Units purchased hereby (without taking into account
any limitations on the exercise of the Warrants set forth therein).

 

13.       Conduct
of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate,
in a Material Adverse Effect.

 

14.       Passive
Foreign Investment Company. The Company shall conduct its business, and shall cause its Subsidiaries to conduct their respective
businesses, in such a manner as will ensure that the Company will not be deemed to constitute a passive foreign investment company
within the meaning of Section 1297 of the Code.

 

15.       Restriction
on Redemption and Cash Dividends. So long as any of the Notes contained in the Units purchased hereby are outstanding, the
Company shall not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the
Company without the prior express written consent of the Investor.

 

16.       Corporate
Existence; Other Matters. So long as any of the Notes or Warrants contained in the Units purchased hereby are outstanding,
the Company covenants and agrees that it may not, without the consent of the Investor: (a) amend the terms of the Notes or the
Warrants contained in the Units purchased hereby; (b) amend the Certificate of Incorporation or Bylaws of the Company in any manner
which would impair or reduce the rights of the holders of the Notes or Warrants contained in the Units purchased hereby; (c) liquidate
or dissolve the Company; (d) enter into any line of business other than a business substantially similar or related to the existing
business of the Company; or (e) dispose of any material assets of the Company with a total value in excess of $3 million.

 

    	17

    	 

    

 

17.       Limitation
on Variable Rate Transactions. So long as any of the Notes or Warrants contained in the Units purchased hereby are outstanding,
the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its
Subsidiaries of Common Shares or Common Share Equivalents (or a combination of units thereof) involving a Variable Rate Transaction,
other than in connection with an Exempt Issuance. The Investor shall be entitled to obtain injunctive relief against the Company
and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without
the necessity of showing economic loss and without any bond or other security being required. “Common Share Equivalents”
means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Shares,
including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares. “Variable
Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that
are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Shares or Common
Share Equivalents either (A) at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies
with the trading prices of or quotations for the Common Shares at any time after the initial issuance of such debt or equity securities
(including, without limitation, pursuant to any “cashless exercise” provision), or (B) with a conversion, exercise
or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security
or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the
market for the Common Shares (including, without limitation, any “full ratchet” or “weighted average”
anti-dilution provisions), (ii) issues or sells any debt or equity securities, including without limitation, Common Shares or
Common Share Equivalents, either (A) at a price that is subject to being reset at some future date after the initial issuance
of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the
business of the Company or the market for the Common Shares, or (B) that is subject to or contains any put, call, redemption,
buy-back, price-reset or other similar provision or mechanism (including, without limitation, a “Black-Scholes” put
or call right) that provides for the issuance of additional debt or equity securities of the Company or the payment of cash by
the Company, or (iii) enters into any agreement, including, but not limited to, an “equity line of credit” (other
than with the Investor), “at-the-market offering” or other continuous offering or similar offering of Common Shares
or Common Share Equivalents, whereby the Company may sell Common Shares or Common Share Equivalents at a future determined price.
“Exempt Issuance” means the issuance of (a) Common Shares or options to employees, officers, directors
or vendors of the Company pursuant to any stock or option plan duly adopted for such purpose, by the Board of Directors or a majority
of the members of a committee of directors established for such purpose, (b) the Units, Notes and Warrants in connection with
the Offering, or any Conversion Shares or Warrant Shares upon the exercise or exchange of or conversion of any Notes or Warrants
issued in the Offering, (c) Common Shares issuable upon the conversion, exercise or exchange of any Common Share Equivalents that
are issued and outstanding on the date of this Agreement, provided that such Common Share Equivalents have not been amended since
the date of this Agreement to increase the number of such securities or Common Shares or to decrease the exercise price, exchange
price or conversion price of such securities, (d) securities issued to the Investor, and (e) securities issued pursuant to acquisitions
or strategic transactions approved by the Board of Directors or a majority of the members of a committee of directors established
for such purpose, which acquisitions or strategic transactions can have a Variable Rate Transaction component, provided that any
such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an
operating company or an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

 

    	18

    	 

    

 

18.       Miscellaneous

 

18.1       Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties (including transferees of the Securities). Nothing in
this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors
and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

 

18.2       Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of Chicago, County of Cook, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

18.3       Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

18.4       Notices.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery
to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient;
if not, then on the next Trading Day, (c) five (5) Trading Days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt. All communications shall be sent to (a) in the case of the Company, to
Quantum Materials Corp., 3055 Hunter Road, San Marcos, TX 78666, Telephone Number: (281) 610-4686, Attention: Craig Lindberg,
with a copy (which shall not constitute notice) to K&L Gates LLP, 1000 Main Street, Suite 2550, Houston, Texas 77002, Telephone
Number: (713) 815-7333, Fax: (713) 815-7301, Attention: Bryce D. Linsenmayer, Esq., and (b) in the case of the Investor, to _________________,
Telephone Number: (___) _____________, Fax: (___________) _________, Attention: ________________, with a copy (which shall not
constitute notice) to ______________________, Telephone Number: (____) ____________, Fax: (____) ___________, Attention: ________________.

 

    	19

    	 

    

 

18.5       Amendments
and Waivers. No provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of
such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercises thereof
or of any other right, power or privilege.

 

18.6       Brokers
or Finder’s Fees. The Company shall indemnify and hold harmless each Investor from any liability for any commission
or compensation in the nature of a broker’s or finders’ fee (and the costs and expenses of defending against such
liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

 

18.7       Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.

 

18.8       Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party
shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically
set forth herein or therein.

 

18.9       Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

18.10       Interpretation.
Unless the context of this Agreement clearly requires otherwise, (a) references to the plural include the singular, the singular
the plural, the part the whole, (b) references to any gender include all genders, (c) “including” has the inclusive
meaning frequently identified with the phrase “but not limited to” and (d) references to “hereunder” or
“herein” relate to this Agreement.

 

18.11       Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Investor
and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in this Agreement and hereby agree
to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would
be adequate.

 

    	20

    	 

    

 

18.12       Fees
and Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement,
except that the Company shall reimburse the Investor for its expenses (including the reasonable legal fees of the Investor’s
counsel) in connection with its due diligence investigation of the Company and the preparation of this Agreement and the transactions
contemplated hereby, up to $10,000, which amount has been paid to the Investor prior to the Effective Date. The Company shall
pay all transfer agent fees (including, without limitation, any fees required for same-day processing of any instruction letter
delivered by the Company and any exercise notice delivered by a Investor), stamp taxes and other taxes and duties levied in connection
with the delivery of any Securities to the Investor.

 

19.       Additional
Defined Terms. In addition to the terms defined elsewhere in this Agreement, the Notes and the Warrants, the following terms
have the meanings set forth in this Section 19:

 

19.1       “1934
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

19.2       “Commission”
means the United States Securities and Exchange Commission.

 

19.3       “Common
Shares” means the common stock, par value $0.001 per share, of the Company.

 

19.4       “Liens”
means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

19.5       “Material
Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability of this Agreement,
or the Notes or the Warrants comprising the Units, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, or (iii) a material adverse
effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement,
or the Notes or the Warrants comprising the Units.

 

19.6       “Registrable
Securities” means (i) the Conversion Shares issuable upon conversion of the Notes contained in the Units (without
taking into account any limitations on the conversion of the Notes set forth therein), (ii) the Warrant Shares issuable upon exercise
of the Warrants contained in the Units (without taking into account any limitations on the exercise of the Warrants set forth
therein), and (iii) any capital stock of the Company issued or issuable with respect to the Conversion Shares or Warrant Shares,
including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event
or otherwise and (2) shares of capital stock of the Company into which the Common Shares are exercised or exchanged and shares
of capital stock of a successor entity into which the Common Shares are converted or exchanged.

 

    	21

    	 

    

 

19.7       “Subsidiary”
means any corporation or other entity of which at least a majority of the securities or other ownership interest having ordinary
voting power for the election of directors or other persons performing similar functions are at the time owned directly or indirectly
by the Company and/or any of its other Subsidiaries.

 

19.8       “Trading
Day” means any day on which the Common Shares are traded on the Trading Market, provided that “Trading
Day” shall not include any day on which the Common Shares are scheduled to trade on the Trading Market for less
than 4.5 hours or any day that the Common Shares are suspended from trading during the final hour of trading on the Trading Market
(or if the Trading Market does not designate in advance the closing time of trading on the Trading Market, then during the hour
ending at 3:00:00 p.m., Chicago time) unless such day is otherwise designated as a Trading Day in writing by the Investor.

 

19.9       “Trading
Market” means the OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized successor thereto);
provided, however, that in the event the Company’s Common Shares are ever listed or traded on The NASDAQ Capital Market,
The NASDAQ Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE MKT, the NYSE Arca, the OTC Bulletin
Board, or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing),
then the “Trading Market” shall mean such other market or exchange on which the Company’s Common Shares are
then listed or traded.

 

19.10       “VWAP”
means the volume weighted average price (the aggregate sales price of all trades of Common Shares during a Trading Day divided
by the total number of Common Shares traded during such Trading Day) of the Common Shares during a Trading Day as reported by
Bloomberg L.P. using the AQR function.

 

[SIGNATURES
ON THE FOLLOWING PAGE]

 

    	22

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	THE
    COMPANY
	 	 	 
	 	QUANTUM
    MATERIALS CORP.
	 	 	                     
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	THE
    INVESTOR:
	 	 	                      
	 	By:	 
	 	Name:
    	 
	 	Title:
    	 

 

    	 

    	 

    

 

EXHIBIT
A

 

FORM
OF NOTE

 

    	 

    	 

    

 

EXHIBIT
B

 

FORM
OF WARRANT

 

    	 

    	 

    

 

EXHIBIT
C

 

INVESTOR
QUESTIONNAIRE

 

    	 

    	 

    

 

Schedule
5.18

 

INDEBTEDNESS

 

	Debtholder	Balance

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]